Core Viewpoint - The company, Prit (002324.SZ), announced that specific shareholders plan to reduce their holdings due to personal financial needs, which may impact the stock's market performance [1] Shareholder Reduction Plans - Shareholder Zhou Wu, holding 5.9853 million shares (0.55% of total shares excluding repurchased shares), plans to reduce his holdings by up to 5.9853 million shares through centralized bidding and block trading [1] - Shareholder Li Hong, the company's deputy general manager, holding 846,400 shares (0.08% of total shares excluding repurchased shares), plans to reduce his holdings by up to 211,600 shares (0.02% of total shares excluding repurchased shares) through similar methods [1]

证券代码：002324 证券简称：普利特 公告编号：2026-007 上海普利特复合材料股份有限公司 关于特定股东及公司高管减持股份的预披露公告 二、本次减持计划的主要内容 特定股东周武先生以及公司副总经理李宏先生保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有本公司股份 5,985,318 股（占公司剔除回购专用证券账户持股数量的总股本比 例 0.55%）的特定股东周武先生因个人资金需求计划通过集中竞价、大宗交易方式合计 减持本公司股份不超过 5,985,318 股（占公司剔除回购专用证券账户持股数量的总股本 比例 0.55%）。 持有本公司股份 846,445 股（占公司剔除回购专用证券账户持股数量的总股本比例 0.08%）的股东、公司副总经理李宏先生因个人资金需求计划通过集中竞价、大宗交易 方式合计减持本公司股份不超过 211,600 股（占公司剔除回购专用证券账户持股数量的 总股本比例 0.02%）。 上海普利特复合材料股份有限公司（以下简称"公司"） 于近日接到公司特定股东 周武先 ...

Group 1 - The modified plastics industry in China has shown a growing trend in investment and financing activities from 2017 to 2025, with a total of 18 financing events recorded [1][5] - The average single financing amount in the modified plastics industry peaked at approximately 450 million RMB in 2022, but is expected to decline to 30 million RMB by 2024-2025 [2][5] - Investment rounds are primarily concentrated in A and B+ rounds, indicating a focus on pre-IPO financing [5][12] Group 2 - The majority of financing events in the modified plastics industry occurred in Beijing, with a total of 7 events from 2017 to 2025, while Jiangsu and Zhejiang also showed high activity [6][8] - The investment focus within the modified plastics sector is heavily directed towards biodegradable plastics, with several significant financing events reported [9][12] - The main investors in the modified plastics industry are primarily investment firms, with notable representatives including Taihe Capital and Sany Innovation [12][14] Group 3 - The modified plastics industry has seen limited mergers and acquisitions, primarily involving horizontal integration among midstream companies [14][15] - A summary of mergers and acquisitions indicates that companies like Daon Technology and Huitong Technology have completed several horizontal integrations, enhancing their market positions [15][18] - Overall, while investment activities in the modified plastics market are on the rise, the number of mergers and acquisitions remains relatively low [18]

每经头条（nbdtoutiao）——曾卖劳斯莱斯、保时捷等豪车，汽车销售巨头宝利德如今破产清算：杭州 总部已人去楼空，义乌子公司贴上了封条 每经AI快讯，普利特2月2日晚间发布公告称，截至本公告日，周文累计质押股数为7875万股，占其所 持股份比例为17.62%。 （记者 曾健辉） ...

Core Viewpoint - The announcement indicates that the controlling shareholder, Zhou Wen, has undertaken procedures to release and pledge part of the company's shares, reflecting a strategic financial maneuver to manage equity and financing [1] Group 1: Share Pledge and Release - Zhou Wen has released 20 million shares from pledge, which accounts for 4.47% of his holdings and 1.80% of the total share capital [1] - Additionally, 16.5 million shares have been pledged, representing 3.69% of his holdings and 1.48% of the total share capital, aimed at replacing pledged financing [1] Group 2: Current Pledge Status - As of the announcement date, Zhou Wen and his concerted parties have a total of 78.75 million pledged shares, which is 17.62% of his holdings [1] - The financing balance corresponding to the pledged shares maturing within the next year is 36.5 million yuan, with repayment sources being self-owned and self-raised funds, indicating no risk of forced liquidation [1]

证券代码：002324 证券简称：普利特 公告编号：2026-006 上海普利特复合材料股份有限公司 关于控股股东部分股份解除质押及股份质押的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、误导性陈述或者重大遗 漏。 上海普利特复合材料股份有限公司（以下简称"公司"）于近日接到公司控股股东、实际 控制人周文先生通知，获悉其将持有的部分公司股权办理了股票解除质押及质押手续，具体事 项如下： 一、股东股份解除质押的基本情况 | | 是否为控股股 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 东或第一大股 | | 本次解除质押 | 占其所持 | 占公司总 | 质押起始 | 质押到期 | 质权人 | | 称 | 东及其一致行 | | 股数（股） | 股份比例 | 股本比例 | 日 | 日 | | | | | 动人 | | | | | | | | 周文 | | 是 | 20,000,000 | 4.47% | 1.80% | 2025/6/20 | 2026/1/30 | 中国银河 ...

长江商报消息 ●长江商报记者 沈右荣 双主业齐发力，普利特（002324.SZ）经营业绩高速增长。 根据普利特最新发布的年度业绩预告，2025年，公司预计实现归母净利润为3.61亿元—4.16亿元，同比 增长1.5倍以上；预计实现扣非净利润3.26亿元至3.81亿元，同比增长逾2倍。 对比2024年普利特营收净利同比均下降，2025年，公司则实现了大逆转。 普利特解释，2025年，公司双主业发力，改性材料板块业务实现高速增长，新能源板块业绩较上年同期 显著改善。 与经营业绩大幅增长相对应的是，普利特的经营现金流大幅回流。2025年前三季度，公司经营现金流净 额为6.89亿元，同比增长203.46%。 备受关注的是，普利特自主研发的一种产品打破了长期垄断。近期，公司披露，公司经过多年研发的 LCP薄膜产品，已开始为某客户的新一代消费电子手机终端的软板天线大批量供货。 2025年前三季度，普利特研发投入3.42亿元。 针对2025年经营业绩增长，普利特解释，公司改性材料板块业务实现高速增长。随着新能源汽车业务占 比的逐步提高，零部件的应用领域进一步扩大以及海外基地新增产能的相继投产，公司汽车材料业务销 量持续增长 ...

Group 1 - Tianqi Co., Ltd. has entered the brain-computer interface (BCI) sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, achieving animal testing stages, and becoming a key player in domestic BCI hardware localization. The developed flexible neural electrode has 1024 channels, with signal acquisition precision and anti-interference capabilities at an internationally advanced level. The company has also completed biocompatibility surface modification technology to reduce inflammation after electrode implantation, with core patents authorized by the National Intellectual Property Administration [1][2][3] - Innovation Medical, through its subsidiary Boling Brain Machine, is one of the first companies in China to commercialize BCI rehabilitation products. The core product, Cyberlink AC5, was officially launched in October 2025, generating sales revenue of 114,000 yuan in 2025. Another product, Cyberlink AM5, has completed multi-center clinical trials and is progressing through the approval process. The company plans to establish five additional clinical cooperation centers to accelerate the application of BCI technology in treating neurological diseases [4][5][6] - iFlytek is a leading company in the non-invasive BCI field, leveraging its artificial intelligence technology to develop BCI collaborative technology. The company has established long-term partnerships with universities for research and development. Its non-invasive BCI system has been piloted in 120 schools nationwide, improving student attention by 30%. In the medical field, a collaboration with Beijing Tiantan Hospital has achieved a 92% accuracy rate in identifying abnormal brain signals for epilepsy [7][8][9] Group 2 - Jiahe Intelligent focuses on the research and mass production of BCI hardware, particularly EEG acquisition devices and core components, serving both consumer and medical-grade markets. The company has achieved large-scale production of EEG acquisition headphones with a signal recognition accuracy of 92%, primarily used in sleep monitoring and attention training. It plans to expand into overseas BCI hardware markets by 2026 [10][11][12] - Tom Cat is the first company in China to apply BCI technology in consumer scenarios, focusing on interactive games and rehabilitation training products. The company launched a mind-controlled game product in 2025, which quickly gained over 500,000 users. It also collaborates with rehabilitation institutions to develop BCI rehabilitation training systems, showing a 35% average improvement in patient motor function scores [13][14][15] - Hanwei Technology, through its subsidiary Weisheng Technology, is a leading company in the EEG sensor field, with an annual shipment of over 2 million units. The company has developed an epilepsy early warning system with an 88% accuracy rate in clinical tests. It also focuses on flexible pressure sensors for invasive BCI electrodes, addressing industry pain points [16][17][18] Group 3 - StarNet Ruijie leverages its network communication technology to develop low-power, high-stability EEG signal transmission systems and data encryption modules, becoming a core supplier for BCI data links. The developed transmission system supports real-time transmission of 1024-channel EEG signals with a latency of less than 10ms and a stability of 99.9% [19][20][21] - Yijiahe focuses on the integration of BCI and embodied intelligent robots, exploring applications in smart healthcare. The company has signed a strategic cooperation agreement to develop real-time emotional companionship and brain-controlled robots, enhancing the emotional care capabilities of robots [22][23][24] - Lihua Technology is focused on incubating and investing in the BCI sector, successfully incubating three high-tech companies in the field. The company collaborates with the Shenzhen Institute of Advanced Technology to provide comprehensive services for incubated companies, addressing development pain points [25][26][27] Group 4 - Sanbo Neurosurgery is a leading private hospital in the neurosurgery field, focusing on the clinical application and research of BCI. The company has successfully conducted an interventional BCI surgery, accumulating valuable experience for clinical applications. It is also recruiting participants for ongoing clinical trials [28][29][30] - Shiyun Circuit is a core enterprise in the PCB field, providing customized PCB products for BCI devices. The company focuses on high-density, flexible PCB designs, achieving low signal loss rates below 2% [31][32][33] - Meihua Medical is a leading supplier of core components for BCI, having entered the core supply chain for invasive BCI products. The company has developed components that have passed biocompatibility tests, ensuring long-term stability and safety for implanted devices [34][35][36]

Core Viewpoint - The report highlights the significant growth driven by technology in certain sectors, while also noting the substantial losses due to cyclical downturns in others [1] Performance Growth Highlights - **Zhongwei Company (688012)**: Expected net profit between 208 million to 218 million yuan, a year-on-year increase of 28.74% to 34.93%, driven by increased recognition of plasma etching equipment and a surge in market demand [5] - **Lianchuang Optoelectronics (600363)**: Expected net profit between 43.5 million to 53.2 million yuan, a year-on-year increase of 80.36% to 120.57%, attributed to significant growth in laser business and improved profitability in traditional sectors [6] - **Ruixin Microelectronics (603893)**: Expected net profit between 102.3 million to 110.3 million yuan, a year-on-year increase of 71.97% to 85.42%, driven by rapid growth in the AIoT market and recognition of new AI technology [7] - **Sangfor Health (688336)**: Expected net profit around 290 million yuan, a year-on-year increase of approximately 311.35%, due to a significant collaboration with Pfizer and advancements in clinical research [8] - **Pulite (002324)**: Expected net profit growth of 155.76% to 194.73%, driven by the demand for high polymer materials in the automotive lightweight trend [9] - **Tonghua Dongbao (600867)**: Expected net profit around 124.21 million yuan, turning from loss to profit, driven by market share gains in insulin products [10] - **Suotong Development (603612)**: Expected net profit between 73 million to 85 million yuan, a year-on-year increase of 167.98% to 212.03%, due to rising prices and demand in the prebaked anode industry [11] Major Performance Declines - **China Shipbuilding Technology (600072)**: Expected net loss between -260 million to -340 million yuan, a year-on-year decline of over 24 times, due to cyclical downturns in shipbuilding and high material costs [12] - **Silver Nonferrous Metals (601212)**: Expected net loss between -45 million to -67.5 million yuan, transitioning from profit to loss due to legal disputes affecting financial performance [13] - **China Metallurgical Group (601618)**: Expected net profit between 130 million to 160 million yuan, a year-on-year decline of 76.28% to 80.73%, impacted by the downturn in the construction industry [14] - **Jindi Group (600383)**: Expected net loss between -1.11 billion to -1.35 billion yuan, with increased losses due to declining sales and inventory impairments [15] - **Jianfa Co. (600153)**: Expected net loss between -1 billion to -520 million yuan, transitioning from profit to loss due to increased impairments in real estate [16] Industry Trend Analysis - **Technology and Innovation-Driven Sectors**: Companies in semiconductor equipment, laser military applications, and innovative pharmaceuticals are experiencing rapid growth due to high demand in AIoT, national defense, and biomedicine [23] - **Traditional Cyclical Industries**: Sectors like coal and engineering machinery are facing significant adjustments due to demand shortages and price declines, leading to widespread performance pressures [24] - **Pharmaceutical Industry Disparities**: Innovative drugs are seeing explosive growth through external licensing, while traditional formulations and raw materials are significantly impacted by procurement policies [24] - **External Environment Uncertainties**: Factors such as international trade tensions and regulatory changes are significantly affecting corporate performance, necessitating enhanced risk management [24] - **Asset Quality Risks**: Many companies are reporting substantial asset impairment provisions, indicating potential inefficiencies in previous investments [24]

登录新浪财经APP 搜索【信披】查看更多考评等级 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：预计净利润为正值且属于同向上升50%以上情形 （1）以区间数进行业绩预告的 单位：万元 二、与会计师事务所沟通情况 本次业绩预告未经过会计师事务所的预审计。公司已就业绩预告有关事项与年报审计会计师事务所进行 了预沟通，公司与会计师事务所在本报告期的业绩预告财务数据方面不存在重大分歧。 三、业绩变动原因说明 证券代码：002324 证券简称：普利特 公告编号：2026-005 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 本次业绩预告是公司财务部门遵循会计准则进行的初步核算，公司尚未发现影响本次业绩预告内容准确 性的重大不确定因素。本次业绩预告相关数据尚未经注册会计师审计。 五、其他相关说明 1、本次业绩预告是公司财务部门初步测算的结果，未经注册会计师审计。 2、2025年年度业绩具体财务数据将在公司2025年年度报告中详细披露。 3、公司指定的信息披露媒体为《中国证券报》《证券时报》《证券日报》《上海证券报 ...